{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-000105","form_type":"8-K","ticker":null,"cik":"0001722964","company_name":"Y-mAbs Therapeutics, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.617169+00:00","generated_at":"2026-05-28T05:19:42.385838+00:00","sec_items":["2.02","2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Y-mAbs realigns into two units, cuts ~13% staff; FY24 rev ~$88M; GD2-SADA data Q2 2025","bullets":["Preliminary FY2024 total net revenue ~$88M (guidance $87-95M); cash ~$67M; cash investment ~$11M (below $15-20M guidance).","Workforce reduction of up to ~13% as part of realignment into DANYELZA and Radiopharmaceutical business units.","SVP/Chief Commercial Officer Susan Smith departs April 9, 2025; Doug Gentilcore named SVP Danyelza Unit Head, Natalie Tucker promoted to SVP Radiopharma Head.","GD2-SADA Phase 1 Part A (21 patients) well-tolerated, no DLTs; Part A data expected in Q2 2025.","CD38-SADA first patient dosing expected Q1 2025; potential DANYELZA ex-US approval in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-000105","json":"https://secwatch.observer/filing/0001558370-25-000105.json","markdown":"https://secwatch.observer/filing/0001558370-25-000105.md","text":"https://secwatch.observer/filing/0001558370-25-000105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1722964/000155837025000105/0001558370-25-000105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1722964/000155837025000105/ymab-20250106x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:19:42.385838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"db48728d74","claim":"Susan Smith departed as Senior Vice President and Chief Commercial Officer at Y-mAbs Therapeutics, Inc..","evidence_excerpt":"Susan Smith, the Company’s Senior Vice President and Chief Commercial Officer, will be departing from the Company on April 9, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1722964/000155837025000105/0001558370-25-000105-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will be departing"},{"label":"Role","value":"Senior Vice President and Chief Commercial Officer"}],"fact_type":"executive_change"},{"claim_id":"c67ad36531619d00119ea9a72547f3285cae93da","claim":"Y-mAbs Therapeutics, Inc. announced a restructuring with charges of up to approximately $2.6 million affecting not explicitly segmented but refers to two business units: DANYELZA and Radiopharmaceuticals (up to approximately 13%).","evidence_excerpt":"healthcare coverage assistance. ​ As a result of the reduction in workforce and realignment plan, the Company expects to incur restructuring expenses of up to approximately $2.6 million, consisting predominantly of cash-related notice and severance payments of up to approximately $2.1 million and acceleration of stock-based compensation of up to approximately","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1722964/000155837025000105/0001558370-25-000105-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"up to approximately $2.6 million"},{"label":"Affected area","value":"not explicitly segmented but refers to two business units: DANYELZA and Radiopharmaceuticals"},{"label":"Headcount","value":"up to approximately 13%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}